Terms: = Leukemia AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Treatment
175 results:
1. Comprehensive characterization of immunogenic cell death in acute myeloid leukemia revealing the association with prognosis and tumor immune microenvironment.
Chen Y; Qiu X; Liu R
BMC Med Genomics; 2024 Apr; 17(1):107. PubMed ID: 38671491
[TBL] [Abstract] [Full Text] [Related]
2. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.
Ferrer-Marín F; Hernández-Boluda JC; Alvarez-Larrán A
Br J Haematol; 2024 May; 204(5):1605-1616. PubMed ID: 38586911
[TBL] [Abstract] [Full Text] [Related]
3. Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial.
van der Maas NG; Versluis J; Nasserinejad K; van Rosmalen J; Pabst T; Maertens J; Breems D; Manz M; Cloos J; Ossenkoppele GJ; Floisand Y; Gradowska P; Löwenberg B; Huls G; Postmus D; Pignatti F; Cornelissen JJ
Blood Cancer J; 2024 Mar; 14(1):56. PubMed ID: 38538587
[TBL] [Abstract] [Full Text] [Related]
4. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
5. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
6. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (calr) in exon 3.
Bonnet S; Carillo S; Legrand B; Burroni B; Lavabre-Bertrand T; Requirand G; Robert N; Fornero L; Al Mansoori A; Moreaux J; Cartron G; Gabellier L; Herbaux C
Eur J Haematol; 2024 Mar; 112(3):475-478. PubMed ID: 37918825
[TBL] [Abstract] [Full Text] [Related]
7. The feasibility of implementing Toronto childhood cancer stage guidelines and estimating the impact on outcome for childhood cancers in seven pediatric oncology units in sub-Saharan Africa. A study from the Franco-African Pediatric Oncology Group.
Mallon B; Kaboré R; Couitchere L; Akonde FB; Narison MLR; Budiongo A; Dackono TA; Pondy A; Diedhiou F; Patte C; Steliarova-Foucher E; Clavel J
Pediatr Blood Cancer; 2023 Dec; 70(12):e30664. PubMed ID: 37732944
[TBL] [Abstract] [Full Text] [Related]
8. Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
Murton A; Forsyth C; Ross DM; Grigg A
Leuk Lymphoma; 2023 Dec; 64(12):2018-2025. PubMed ID: 37574855
[TBL] [Abstract] [Full Text] [Related]
9. Enhancing information on stage at diagnosis for childhood cancer in Africa.
Liu B; Abraham N; Chitsike I; Sylvie CGL; Kambugu J; Stévy NMA; Pondy AHO; Renner L; Parkin DM
Pediatr Blood Cancer; 2023 Oct; 70(10):e30555. PubMed ID: 37432023
[TBL] [Abstract] [Full Text] [Related]
10. PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions.
Chen J; Li M; Liu Y; Guan T; Yang X; Wen Y; Zhu Y; Xiao Z; Shen X; Zhang H; Tang H; Liu T
Cell Death Differ; 2023 Apr; 30(4):1082-1095. PubMed ID: 36813923
[TBL] [Abstract] [Full Text] [Related]
11. How I manage anemia related to myelofibrosis and its treatment regimens.
Verstovsek S
Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
[TBL] [Abstract] [Full Text] [Related]
12. Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in
Wang Y; Ran F; Lin J; Zhang J; Ma D
Technol Cancer Res Treat; 2023; 22():15330338231154092. PubMed ID: 36744404
[TBL] [Abstract] [Full Text] [Related]
13. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
Chiappella A; Dodero A; Evangelista A; Re A; Orsucci L; Usai SV; Castellino C; Stefoni V; Pinto A; Zanni M; Ciancia R; Ghiggi C; Rossi FG; Arcari A; Ilariucci F; Zilioli VR; Flenghi L; Celli M; Volpetti S; Benedetti F; Ballerini F; Musuraca G; Bruna R; Patti C; Leonardi F; Arcaini L; Magagnoli M; Cavallo F; Bermema A; Tucci A; Boccomini C; Ciccone G; Carniti C; Pileri SA; Corradini P
Leukemia; 2023 Feb; 37(2):433-440. PubMed ID: 36653509
[TBL] [Abstract] [Full Text] [Related]
14. calr-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.
Jutzi JS; Marneth AE; Jiménez-Santos MJ; Hem J; Guerra-Moreno A; Rolles B; Bhatt S; Myers SA; Carr SA; Hong Y; Pozdnyakova O; van Galen P; Al-Shahrour F; Nam AS; Mullally A
Leukemia; 2023 Feb; 37(2):359-369. PubMed ID: 36473980
[TBL] [Abstract] [Full Text] [Related]
15. The risks of birth defects and childhood cancer with conception by assisted reproductive technology.
Luke B; Brown MB; Wantman E; Schymura MJ; Browne ML; Fisher SC; Forestieri NE; Rao C; Nichols HB; Yazdy MM; Gershman ST; Sacha CR; Williams M; Ethen MK; Canfield MA; Doody KJ; Eisenberg ML; Baker VL; Williams C; Sutcliffe AG; Richard MA; Lupo PJ
Hum Reprod; 2022 Oct; 37(11):2672-2689. PubMed ID: 36112004
[TBL] [Abstract] [Full Text] [Related]
16. Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda.
Kizub DA; Naik S; Abogan AA; Pain D; Sammut S; Shulman LN; Martei YM
Oncologist; 2022 Nov; 27(11):958-970. PubMed ID: 36094141
[TBL] [Abstract] [Full Text] [Related]
17. Impact of molecular profiling on the management of patients with myelofibrosis.
Pastor-Galán I; Martín I; Ferrer B; Hernández-Boluda JC
Cancer Treat Rev; 2022 Sep; 109():102435. PubMed ID: 35839532
[TBL] [Abstract] [Full Text] [Related]
18. Secondary chronic myeloid leukemia in a patient with calr and ASXL1-mutated primary myelofibrosis.
Sobieralski P; Bieniaszewska M; Leszczyńska A; Żuk M; Wasąg B; Zaucha JM
Int J Hematol; 2022 Sep; 116(3):442-445. PubMed ID: 35429330
[TBL] [Abstract] [Full Text] [Related]
19. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Konopleva MY; Röllig C; Cavenagh J; Deeren D; Girshova L; Krauter J; Martinelli G; Montesinos P; Schäfer JA; Ottmann O; Petrini M; Pigneux A; Rambaldi A; Recher C; Rodriguez-Veiga R; Taussig D; Vey N; Yoon SS; Ott M; Muehlbauer S; Beckermann BM; Catalani O; Genevray M; Mundt K; Jamois C; Fenaux P; Wei AH
Blood Adv; 2022 Jul; 6(14):4147-4156. PubMed ID: 35413116
[TBL] [Abstract] [Full Text] [Related]
20. Differences in the diagnosis and treatment of hematologic malignancies attributable to health insurance coverage.
Song EY; Shin S; Park H; Kim N; Yoon JH; Roh EY
Medicine (Baltimore); 2022 Mar; 101(9):e29020. PubMed ID: 35244084
[TBL] [Abstract] [Full Text] [Related]
[Next]